IMNM — Immunome Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1472012 ·
Last close
$17.18
Market Cap
$2.03B
52W High
$30.06
52W Low
$16.41
ADV30
1,476,317
Next earnings
2026-11-10
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -90,362,000 -85,783,000 505,527,000 212,842,000 51,224,000
Jun 2026 0 — -78,135,000 -73,127,000 565,384,000 217,706,000 40,301,000
Mar 2026 0 — -59,331,000 -53,839,000 619,792,000 582,693,000 31,106,000
Dec 2025 0 — -72,861,000 -69,900,000 683,188,000 653,482,000 48,845,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-229,034,000
Investing CF
$-266,857,000
Financing CF
$436,094,000
CapEx
$-18,680,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.54
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-940,913,000
Inventory
—
Receivables
—
ST Investments
$248,740,000
EBIT TTM
$-300,689,000
Pretax Income TTM
$-282,649,000
Interest Exp TTM
—
Analysts
15

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-287,496,000
Free Cash Flow
$-159,733,632
Enterprise Value
$1,766,032,128
Total Cash
$461,582,016
Total Debt
$11,385,000
Shares Out
118,072,943
Trailing EPS
$-2.63
Book Value
$4.00
ROE
-78.7%
ROA
-45.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 6,941,000 -224,113,000 -212,394,000 683,188,000 48,845,000 634,343,000 -190,919,000
Dec 2024 9,041,000 -153,456,000 -292,963,000 240,241,000 59,076,000 181,165,000 -110,794,000
Dec 2023 14,018,000 -28,728,000 -106,806,000 148,540,000 28,658,000 119,882,000 -7,568,000
Dec 2022 0 -36,901,000 -36,896,000 24,046,000 7,393,000 16,653,000 -28,690,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-254,323,000
OpCashFlow TTM
—
Assets (Latest)
$565,384,000
Forward EPS
$-2.55

Max Pain — expiry 2028-01-21

max pain strike: $25.00 · spot: $16.78 · call oi: 409 · put oi: 2,678
Expected Move to 2028-01-21: ±$21.50 (128.13%) — implied range $-4.72 – $38.28 · ATM straddle on $18.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BHVN Biohaven Ltd. $2.00B $13.24 —
AUPH Aurinia Pharmaceuticals Inc. $2.06B $15.40 —
PVLA PALVELLA THERAPEUTICS, INC. $2.11B $144.35 —
HRMY Harmony Biosciences Holdings, Inc. $1.94B $33.01 —
TRVI Trevi Therapeutics, Inc. $1.93B $13.51 —

News headlines (Yahoo Finance, 1h cache)

Immunome to Present at Upcoming Investor Conferences
2026-11-18 12:30 · Yahoo
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 21:02 · Yahoo
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:00 · Yahoo
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
2026-11-04 14:01 · Yahoo
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know
2026-11-04 13:55 · Yahoo
Immunome Stock Gets EMA Review For Desmoid Tumor Drug
2026-11-02 23:14 · Yahoo
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 12:30 · Yahoo
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
2026-10-30 11:30 · Yahoo
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
2026-10-26 11:00 · Yahoo
Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus
2026-10-13 22:16 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.